Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL0605 timing in breast cancer chemotherapy
NCT06616571Phase 4Recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Sep 2024
- Primary completion
- Dec 2025
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of pegfilgrastim-qilo in febrile neutropenia (FN) (2 arms), sponsored by Qilu Pharmaceutical. Primary endpoint: Incidence of febrile neutropenia for chemotherapy cycle 1 at 21 days. Started Sep 2024; status: recruiting.
02
Drugs
pegfilgrastim-qilo
03
Conditions
febrile neutropenia (FN)
Beyond the preview
Go deeper on NCT06616571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06616571.